Loading candles…
Kopran Ltd. operates in the pharmaceutical industry, manufacturing and supplying pharmaceutical formulations and active pharmaceutical ingredients (APIs) worldwide. The company serves both regulated and non-regulated markets across more than 50 countries. Kopran Ltd. conducts its operations through its formulations segment and its wholly-owned subsidiary, Kopran Research Laboratories Ltd. (KRLL). Its product portfolio includes a diverse therapeutic range focusing on cardiovascular, anti-diabetic, and anti-infective segments. Kopran Ltd. specializes in delivering pharmaceutical products globally, addressing various healthcare needs through its formulations and API verticals.
This page is a live market overview for KOPRAN LTD (KOPRAN) on the NSE. As a listed security, KOPRAN LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for KOPRAN before placing trades on tick2trade.
As of the latest feed, KOPRAN last traded at ₹181.22 on NSE, down ₹9.44 (4.95%) from the previous close of ₹190.66. Today's session range is ₹181.13 – ₹190.66, against a 52-week band of ₹107 – ₹219. Traded volume today stands at 2.82L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for KOPRAN in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether KOPRAN is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for KOPRAN LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in KOPRAN. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated KOPRAN option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 7 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 19 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 22 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 12 Nov 2025 |
| Unaudited Results - FY25 | To consider and approve the unaudited financial results for the period ended Jun 30, 2025 | 29 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 15 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.